Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.

Annals of the rheumatic diseases - 1 May 2017

Miyabe Chie, Miyabe Yoshishige, Strle Klemen, Kim Nancy D, Stone John H, Luster Andrew D, Unizony Sebastian

Abstract excerpt

OBJECTIVES: Randomised-controlled trials have recently proven the efficacy of the interleukin (IL)-6 receptor antagonist tocilizumab (TCZ) in giant cell arteritis (GCA). However, the mechanism of action of IL-6 blockade in this disease is unknown. Moreover, the role of regulatory T (Treg) cells in the pathogenesis of GCA remains underexplored. Given the plasticity of Tregs and the importance of IL-6 in their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Anti-Inflammatory Agents, Non-Steroidal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to CTLA-4 Antigen

Share to Giant Cell Arteritis

Share to Interleukin-17

Share to Interleukin-2 Receptor alpha Subunit

Share to Lymphocyte Count

Source

Open in PubMed Open full text

Identifiers

PMID: 27927642
DOI: 10.1136/annrheumdis-2016-210070
PMCID: PMC5744591

Genes

GCA
CCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.PMID 27927642Read ↗

Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis.Semantic proximity Read ↗

Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.Semantic proximity Read ↗

Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8+ T cells in giant cell arteritis.Semantic proximity Read ↗

Inflammatory Cell Composition and Immune-Related microRNA Signature of Temporal Artery Biopsies From Patients With Giant Cell Arteritis.Semantic proximity Read ↗

A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis.Semantic proximity Read ↗

Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis.Semantic proximity Read ↗

Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis.Semantic proximity Read ↗

Longitudinal expression profiling of CD4+ and CD8+ cells in patients with active to quiescent Giant Cell ArteritisSemantic proximity Read ↗

Longitudinal expression profiling of CD4+ and CD8+ cells in patients with active to quiescent giant cell arteritis.Semantic proximity Read ↗

CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?Semantic proximity Read ↗

Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsiesSemantic proximity Read ↗

Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.